$ENVA

Fisher David sold $1.2M of ENVA

Fisher David (Executive Chairman) sold 7,180 shares of Enova International, Inc. (ENVA) at $160.37 ($1.15M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fisher David
Published May 26, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ENVA
Neutral
medium confidence
Mentioned
$ENVA
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENVANeutralMed
01

Why it matters

The disclosure provides information about insider liquidity and potential sentiment, but the presence of a pre-arranged 10b5-1 plan generally lowers the probability of a fundamental negative signal.

02

Market read

ENVA receives a Form 4 showing an executive chairman open-market sale (~$1.15M) under 10b5-1, which may cause limited short-term sentiment pressure.

03

What to watch

Traders may overreact to the headline dollar amount; the key nuance is the pre-arranged plan and the relatively small post-sale ownership change versus total shares.

Relevance 8/10Timing: Potential short-term sentiment/positioning impact as traders digest the Form 4 filing; no immediate catalyst beyond disclosure.

Background

The article is an SEC Form 4 insider transaction disclosure for Enova International, Inc. (ENVA).

Company-level read

Ticker impact

$ENVANeutralMedium confidence
Context

Enova executive chairman David Fisher sold $1.15M of ENVA shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low-to-moderate near-term downside/volatility risk around the filing date; longer-term impact likely limited.

Evidence & confidence

The filing specifies an open-market sale and a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal—this is company-specific insider activity without broader sector/regulatory signals.

None indicated; US-listed issuer disclosure only.

None indicated; no cross-border deal or operational update mentioned.

Counterpoint

The sale may reflect routine liquidity/portfolio rebalancing under a 10b5-1 plan rather than negative expectations.

Key entities

  • Enova International, Inc.

    Subject of the Form 4 insider sale by executive chairman David Fisher.

  • David Fisher

    Executive Chairman who sold 7,180 ENVA shares under a pre-arranged 10b5-1 plan.

Related articles

$OPFIMed

OppFi and Enova Bank Deals Put Lending Under Scrutiny

Attorneys general asked the Federal Reserve, OCC and FDIC to deny banking privileges tied to OppFi’s $130M acquisition of BNCCORP and BNC National Bank and Enova’s proposed acquisition of Grasshopper Bancorp and Grasshopper Bank. AGs allege bank partnerships bypass state loan-rate caps and cite high rates and charge-offs. OppFi and Enova project deposit and revenue synergies and EPS accretion.

$ENVAMed

ENVA Rallies As Enova Tops Q2 And Targets Grasshopper Bank Synergies

Enova International Inc. (NYSE: ENVA) shares rose about 9% after Q2 results and guidance-related optimism. The company reported adjusted EPS of $4.31 vs $3.96 consensus and revenue of $928.9M vs $764M prior year, with operating cash flow of $544M and $531.4M free cash flow. Analysts reportedly raised price targets to $257-$280, citing the Grasshopper Bank acquisition and improving credit metrics.

$ENVAMedAI 8/10

Enova International Stock Jumps After Powerful Q2 Beat

Enova International Inc. (NYSE: ENVA) shares rose about 9% during the week after the company reported Q2 2026 results and raised guidance. Adjusted EPS was $4.31 versus $3.96 expected, with revenue up to $928.9M from $764M. Management cited record $5.5B loans, improving margins, and ongoing share repurchases.

$ENVAMed

ENVA Jumps As Enova Earnings Beat Fuels Bullish Targets

Enova International Inc. (NYSE: ENVA) shares rose about 9% after its Q2 2026 results. The company reported adjusted EPS of $4.31 versus $3.23 a year earlier and revenue of $928.9M versus $764M, alongside a consumer credit outlook. Analysts cited bullish targets of $257 to $280 and support near $230.

$ENVAMedAI 8/10

Enova International Signals Strong Growth and Rising EPS

Enova International (ENVA) reported Q2 results and said consolidated originations rose 27% YoY to nearly $2.3B and total revenue rose 22% to $929M. Adjusted EPS increased 33% YoY to $4.31. Credit metrics improved, with net charge-offs at 7.3%. Management raised Q3 and 2026 guidance and noted the pending Grasshopper Bank deal awaits regulatory approval.

$ENVAMedAI 8/10

Enova Reports Second Quarter 2026 Results

Enova International (NYSE: ENVA) reported Q2 2026 results. Total revenue rose 22% to $929 million. Diluted EPS was $4.00, up 40%, and adjusted EPS was $4.31, up 33%. Credit metrics stayed strong, with net charge-offs at a 7.3% ratio and net revenue margin at 61%. Enova also repurchased $19 million of stock and reported $929 million liquidity at June 30.